This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Raman, M. Articles by Allard, J. P. Search for Related Content PubMed PubMed Citation Articles by Raman, M. Articles by Allard, J. P. Social Bookmarking                   What's this?

Metabolic Bone Disease in Patients Receiving Home Parenteral Nutrition: A Canadian Study and Review

From the University Health Network, Toronto, Canada

Correspondence: Johane Allard, MD, 585 University Ave, 9N-973, Toronto, ON, Canada M5G 2C4. Electronic mail may be sent to johane.allard{at}uhn.on.ca.

Background: Metabolic bone disease (MBD) is a significant complication in patients receiving long-term home parenteral nutrition (HPN). Pamidronate has been poorly studied in this population. We examine the prevalence and risk factors for MBD and examine changes in bone mineral density (BMD) after pamidronate administration. Methods: First, a chart review of patients receiving HPN for >1 year was performed, and Pearson correlations were used to assess associations between MBD (defined as t score <–1) and risk factors. Second, the effect of IV pamidronate on BMD was studied prospectively in 11 HPN patients. Results were compared using a t-test. Results: Charts were reviewed in 25 patients (15 F, 10 M): age, 56.9 ± 3.1 years; body mass index (BMI), 21.2 ± 0.57 kg/m²; months receiving HPN, 113.2 ± 0.09; and days per week receiving HPN, 5.08 ± 0.39. MBD was present in 33% of patients for the spine and hip and in 50% for the femoral neck; 24% had previous fractures. There was a significant negative correlation between the duration of HPN and BMD (r = –0.40) for all measurements. From those patients, 11 received IV pamidronate for a mean of 22.2 ± 5.4 months. At baseline, their mean HPN treatment duration was 10.6 ± 6.3 years. Overall, BMD results showed a trend toward improvement in the mean t score of the spine and hip postpamidronate therapy (pre, –3.1 ± 0.75; post, –2.9 ± 0.69; p = .07). After excluding 2 patients receiving corticosteroids, the mean t score of the spine showed significant improvement (prepamidronate –3.4 ± 0.57 vs post-pamidronate –3.1 ± 0.65, p = .036). Conclusions: In our HPN population, 76% had MBD and 24% had previous fractures. The results suggest that these patients may benefit from pamidronate. More studies are needed to assess the efficacy of pamidronate.

Journal of Parenteral and Enteral Nutrition, Vol. 30, No. 6, 492-496 (2006)
DOI: 10.1177/0148607106030006492


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Ferrone and M. Geraci A Review of the Relationship Between Parenteral Nutrition and Metabolic Bone Disease Nutr Clin Pract, June 1, 2007; 22(3): 329 - 339. [Abstract] [Full Text] [PDF]